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Abstract
Background: Schizophrenia patients exhibit impairment in prepulse inhibition (PPI) of the acoustic
startle response (ASR) suggesting a sensorimotor gating deficit. The serotonin-2A receptor (5-HT2AR)
has been implicated in both the pathogenesis of schizophrenia and the PPI deficits of schizophrenia
patients. Moreover, both schizophrenia and PPI are thought to be inheritable. Thus, we investigated the
impact of three 5-HT2AR polymorphisms (A-1438G, T102C, H452Y) on PPI in schizophrenia patients.
Methods: We analyzed the 5-HT2AR A-1438G, T102C, and H452Y polymorphisms and assessed startle
reactivity, habituation, and PPI of ASR in 68 Caucasian schizophrenia inpatients. Patients were also
examined with the Positive and Negative Syndrome Scale.
Results: The 5-HT2AR A-1438G and T102C polymorphisms were in complete linkage disequilibrium.
Patients carrying the T102C TT and the A-1438G AA allele show significantly higher PPI levels and a
faster early habituation compared to all other variants. 5-HT2AR A-1438G and T102C genotype
explained about 11% of the PPI and early habituation variance. In contrast, the 5-HT2AR H452Y
polymorphism did not affect startle parameter.
Conclusions: Our findings suggest that PPI and habituation are modulated by 5-HT2AR A-1438G and
T102C genotype in schizophrenia. Consequently, alterations within brain 5-HT2ARs may contribute to
the PPI deficits in schizophrenia. 
5-HT2A polymorphism and PPI in schizophrenia   Quednow et al. 
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Abstract 
Background: Schizophrenia patients exhibit impairment in prepulse inhibition (PPI) of the acoustic 
startle response (ASR) suggesting a sensorimotor gating deficit. The serotonin-2A receptor (5-HT2AR) 
has been implicated in both the pathogenesis of schizophrenia and the PPI deficits of schizophrenia 
patients. Moreover, both schizophrenia and PPI are thought to be inheritable. Thus, we investigated 
the impact of three 5-HT2AR polymorphisms (A-1438G, T102C, H452Y) on PPI in schizophrenia 
patients. 
Methods: We analyzed the 5-HT2AR A-1438G, T102C, and H452Y polymorphisms and assessed 
startle reactivity, habituation, and PPI of ASR in 68 Caucasian schizophrenia inpatients. Patients were 
also examined with the Positive and Negative Syndrome Scale. 
Results: The 5-HT2AR A-1438G and T102C polymorphisms were in complete linkage disequilibrium. 
Patients carrying the T102C TT and the A-1438G AA allele show significantly higher PPI levels and a 
faster early habituation compared to all other variants. 5-HT2AR A-1438G and T102C genotype 
explained about 11% of the PPI and early habituation variance. In contrast, the 5-HT2AR H452Y 
polymorphism did not affect startle parameter. 
Conclusions: Our findings suggest that PPI and habituation are modulated by 5-HT2AR A-1438G and 
T102C genotype in schizophrenia. Consequently, alterations within brain 5-HT2ARs may contribute to 
the PPI deficits in schizophrenia.  
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Introduction 
Schizophrenia patients consistently show an impairment of early information processing as indexed by 
decreased prepulse inhibition (PPI) of the acoustic startle response (ASR)(1). PPI is a substantial 
reduction of the startle amplitude that occurs when a distinctive non-startling stimulus is presented 30-
500 msec before the startling stimulus (2). This mechanism is thought to regulate sensory input by 
filtering out irrelevant or distracting stimuli to prevent sensory information overflow. PPI is used as an 
operational measure of sensorimotor gating (3). 
The serotonin-2A receptor (5-HT2AR) has been implicated in the pathogenesis of schizophrenia (4) and 
in the therapeutic action of atypical antipsychotics (5). Additionally, significant associations of the 
T102C and A-1438G 5-HT2AR polymorphism (which are both in strong linkage disequilibrium) with 
schizophrenia and with symptom improvement following clozapine-treatment have been reported, 
especially in European samples (6-9).  
Considerable evidence suggests that 5-HT2AR function plays an important role in the sensorimotor 
gating deficits of schizophrenia patients as well. Hallucinogenic 5-HT2AR agonists disrupt PPI in 
rodents and – at short lead intervals – also in humans (10,11). Moreover, atypical antipsychotics 
(especially clozapine) seem to be superior in the restoration of PPI deficits in schizophrenia patients 
when compared to typical substances – supposedly because of the 5-HT2AR antagonism of atypical 
agents (12).  
Schizophrenia is an inheritable disease (13) and PPI is also thought to be under strong genetic 
influences (14). Diverse inbred strains of rodents display significant differences in PPI (15,16), and 
unaffected first-degree relatives of schizophrenia patients exhibit decreased PPI levels (17). It has been 
recently estimated that the heritability of PPI in schizophrenia patients and their families is about 32%, 
whereas another study reported a heritability of 50% within a healthy twin sample (18,19).  
Given that both PPI and schizophrenia are inheritable and that schizophrenia and PPI deficits in 
schizophrenia have been linked to 5-HT2AR function, we investigated the impact of the three most 
studied 5-HT2AR polymorphisms (T102C, A-1438G, and H452Y) on PPI in a sample of schizophrenia 
patients. 
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Methods and Materials  
Participants 
Seventy-one schizophrenia inpatients admitted to the Psychiatric Hospital of the University of Bonn 
were considered eligible for the study if the following criteria were met: a diagnosis of schizophrenia 
according to DSM-IV, age between 18 and 65 years, and Caucasian ethnicity. Patients were excluded 
if they had a history of a neurological disease, substance dependency, or a severe somatic disease. 
Every patient was evaluated by a Structured Clinical Interview (SCID-I) according to DSM-IV. 
Clinical symptoms were measured with the Positive and Negative Syndrome Scale (PANSS) (20). 
Fourteen patients were unmedicated, 12 patients received typical antipsychotics, and 44 patients were 
treated with one or more atypical drugs. Demographic and clinical data of the patients are shown in 
Table 1. This study was approved by the Ethics Committee of the Medical Faculty of the University of 
Bonn. After receiving a written and oral description of the aim of this study, all participants gave 
written informed-consent statements before inclusion. 
 
****Insert Table 1*** 
 
Genotyping 
The three 5-HT2AR SNPs (rs6311 [A-1438G], rs6313 [T102C], rs6314 [H452Y]) were analyzed by 
Taqman® Assays (Applied Biosystems, Foster City, CA, USA). The procedure is described in detail 
in the supplemental material. 
 
****Insert Supplemental Material*** 
 
Startle Response Measurement 
PPI was recorded and analyzed as described in our previous work (21). In brief, subjects received 73 
sound pulses with a power of 116 dB along with 70 dB background white noise. In 36 of the trials, the 
pulse was preceded by an 86-dB prepulse with an interstimulus interval (ISI) of 120 ms. The eye-blink 
component of the ASR (right eye) was measured using an electromyographic startle system (San 
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Diego Instruments, San Diego, CA). Smoking ad libitum was permitted before testing (22). Three 
patients (4.2%) with error trials greater than 50% were excluded from data analysis.  
 
Statistical analysis 
The calculation of the mean percent PPI and the habituation measures (percent habituation and linear 
gradient coefficient b) have been described in detail elsewhere (21). Startle reactivity was assessed by 
the mean amplitude of the first block of pulse-alone trials and the mean amplitude of all pulse-alone 
trials. The data were analyzed by analysis of variance with exception of frequency data. Frequency 
data were analyzed using χ2 -Tests. Given that gender (23), smoking (22), antipsychotic medication 
status (unmedicated, typical or atypical antipsychotic drug) (12), and age (24) could affect startle 
parameters, these variables were introduced as covariates in analyses of covariance (ANCOVA). 
Based on significant main effects, Least Significant Difference (LSD) post-hoc comparisons were 
performed. The confirmatory statistical comparisons were carried out at a significance level set at 
p<.05 (2-tailed). 
 
 
Results 
5-HT2A T102C and A-1438G receptor polymorphisms 
The 5-HT2AR T102C and A-1438G polymorphisms were in complete linkage disequilibrium. 
Genotype frequencies were distributed in accordance to the Hardy-Weinberg Equilibrium (HWE; 
Chi2(1)=0.42, p=.52). With exception of gender, the groups did not differ regarding demographic and 
clinical data (see Table 1). The number of men was significantly higher in the homozygous T102C-
T/A-1438G-A group when compared the homozygous T102C-C/A-1438G-G group [Chi2(1)=6.1, 
p=.01]. 
Both PPI and early startle habituation were affected by genotype in separate ANCOVAs corrected for 
gender, age, smoking, and medication status (see Table 2). PPI significantly decreased with the 
number of T102C-C alleles [linear contrast: p<0.01]. LSD post-hoc tests revealed that homozygous 
carriers of the T102C-T/A-1438G-A allele did show significantly higher PPI levels compared to 
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homozygous T102C-C/A-1438G-G [p<.01, d=0.98] and the heterozygous T102C-TC/A-1438G-AG 
variants [p<.05, d=0.67]. With respect to early habituation, only the homozygous variants differed 
significantly from each other [p<.01, d=93]. Early startle habituation was not significantly correlated 
with PPI [r=0.11, p=.39]. Finally, there were trends toward a faster total habituation within the 
homozygous T102C-T/A-1438G-A carriers. 
The effects of T102C/A-1438G genotype on PPI and early habituation remained significant even after 
introduction of symptom severity (PANSS total score) as a further covariate as well as after exclusion 
of female patients from ANCOVA analyses. 
 
****Insert Table 2*** 
 
5-HT2A Y452H receptor polymorphism 
The 5-HT2AR Y452H genotype frequencies were 88.2% (n=60) for the His/His variant and 11.8% 
(n=8) for the His/Tyr variant, which is in concordance with the HWE [Chi2(1)=0.27, p=.61]. Both 
groups did not differ about demographic or clinical characteristics (data not shown). The 5-HT2AR 
Y452H polymorphism did not show any impact on startle parameters in ANCOVAs analyses (all F-
values for the factor genotype were <0.5).  
 
 
Discussion 
The present study provides first evidence that the linked 5-HT2AR T102C/A-1438G polymorphisms 
have a strong impact on sensorimotor gating in schizophrenia patients. Carriers of the T102C-C/A-
1438G-G allele exhibit a significantly lower PPI than patients homozygous for the T102C-T/A-
1438G-A allele. Lower PPI in carriers of the 5-HT2AR T102C-C variant is consistent with the 
association of this allele with schizophrenia (6,8) and with poor long-term outcome and poor response 
to antipsychotics (7,25). In agreement with previous literature, the total group of schizophrenia 
patients did show significantly decreased PPI levels when compared to equivalent groups of healthy 
controls (n=46, 56.9%, SEM 3.2), which were assessed with the same startle paradigm in our previous 
work [t(112)=3.06; p<.01] (21,26). 
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The human 5-HT2AR gene is located on chromosome 13q14-q21. The T102C polymorphism is silent 
and does not result in an alteration of the amino acid sequence of the 5-HT2AR (27). However, the 
T102C polymorphism is located in exon 1 near the promoter region and may therefore play a role in 
gene regulation and expression (28). In fact, recent studies suggest that the C-allele is associated with 
diminished 5-HT2AR expression (29,30). The A-1438G polymorphism is located directly within the 
promoter region of the 5-HT2AR gene (9) and it has been proposed that the A-1438G polymorphism 
alters promoter activity and expression of 5-HT2ARs (31). In sum, the C-allele of the of the T102C 
variation and the G-allele of the A-1438G variation may cause lower 5-HT2AR densities in some brain 
areas that may lead to a less flexible serotonin system and worse dopaminergic modulation (28). This 
conclusion would fit with the findings of decreased 5-HT2AR densities in the cortex of schizophrenia 
patients as well as with the reported association of the T102C-C allele with schizophrenia (6,8). Thus, 
the present data strongly support the view that sensorimotor gating deficits in schizophrenia are linked 
to a genetically altered 5-HT2AR function (10,11). 
Candidate gene effects on PPI in humans have been explored in two other recent studies. A mutation 
on the neuregulin-1 gene (rs3924999) revealed a significant effect on PPI in healthy volunteers and 
schizophrenia patients (32), explaining 7.9% of the PPI variance (in comparison, the 5-HT2AR 
T102C/A-1438G polymorphism explained 11% PPI variance). In contrast, neither COMT Val158Met 
nor DRD2 Taq 1a polymorphism did show an influence on PPI in a sample of healthy female 
volunteers (33).  
 
In the present study, early habituation of the ASR was influenced by 5-HT2AR genotype as well, which 
is in accordance with previous findings that 5-HT2AR agonists and indirect serotonin agonists attenuate 
habituation in rodents and humans (34-36). However, it is still under debate if schizophrenia patients 
display habituation deficits (see 21 for further discussion). In the present sample, schizophrenia 
patients have indeed shown worse habituation when compared to healthy controls from our previous 
studies [t(112)=2.51; p<.05] (21,26). However, they also display a diminished startle reactivity that 
might account for the habituation deficit [t(112)=2.10; p<.05] because both parameters were strongly 
correlated [r=-0.57, p<.001] (see also 21). 
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Taken together, the present findings strongly suggest that PPI and habituation of the ASR are 
modulated by 5-HT2AR A-1438G and T102C genotype in schizophrenia. However, every case-
controlled association study has the limitation of being possibly spurious due to population 
stratification. Therefore, while being biologically plausible, this novel finding is in need of replication 
in larger samples of schizophrenia patients and healthy controls.  
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Table 1 Demographic and clinical characteristics of schizophrenia patients grouped according to their 5-HT2A A-1438G and T102C receptor 
genotype (Means and standard deviation of means in parentheses; sex and smoking in frequency data). 5-HT2A A-1438G and T102C 
receptor polymorphisms were in complete linkage disequilibrium (100% concordance between the alleles). 
 
5-HT2A A-1438G genotype (rs6311) AA AG GG     
5-HT2A T102C genotype (rs6313) TT TC CC Total F/Chi2 df/dferr p 
N 12 (17.6%) 30 (44.1%) 26 (38.2%) 68 (100%)    
Age 29.2 (8.5) 36.1 (11.5) 35.7 (10.0) 34.8 (10.6) 2.10 2/67 .13 
Years of education 14.6 (3.4) 14.5 (3.0) 14.2 (3.0) 14.4 (3.0) 0.09 2/67 .93 
Men in % 91.7 73.3 50.0 67.6 7.31 2 .03 
Smoker in % 66.7 46.7 57.7 54.4 1.57 2 .46 
Patients with a first-episode in % 83.3 56.7 65.4 64.7 2.68 2 .26 
Age of onset  28.7 (8.4) 30.4 (8.7) 31.5 (10.9) 30.5 (9.5) 0.35 2/67 .70 
Number of episodes 1.3 (0.6) 2.3 (2.1) 2.0 (1.6) 2.0 (1.8) 1.66 2/67 .20 
Medication status in % 
(unmedicated/typical/atypical antipsychotic) 
25/8/67 27/13/60 15/27/58 22/18/60 3.15 4 .53 
PANSS Positive 14.6 (7.5) 18.9 (6.9) 19.3 (8.5) 18.3 (7.7) 1.54 2/67 .22 
PANSS Negative 17.4 (7.8) 22.0 (6.7) 20.8 (8.0) 20.7 (7.5) 1.55 2/67 .22 
PANSS General 35.0 (15.1) 40.4 (12.9) 43.2 (14.8) 40.6 (14.1) 1.31 2/67 .28 
PANSS Total 67.0 (28.6) 82.4 (22.4) 83.3 (29.0) 80.2 (26.4) 1.68 2/67 .19 
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Table 2 Adjusteda means and standard error of means (in parentheses) of startle amplitude, prepulse inhibition, and habituation of the acoustic startle 
response of schizophrenia patients grouped according to their 5-HT2A A-1438G and T102C receptor genotype. 5-HT2A A-1438G and T102C 
receptor polymorphisms were in complete linkage disequilibrium. 
 
5-HT2A A-1438G genotype (rs6311) AA AG GG      
5-HT2A T102C genotype (rs6313) TT TC CC Total Fa df/dferra p
a η2a
N 12 (17.6%) 30 (44.1%) 26 (38.2%) 68 (100%)     
First block, amplitude of pulse-alone trials 
(Arbitrary units) 
305 (54.2) 240 (33.8) 294 (36.8) 272 (23.6) 0.79 2/61 .46 .03 
Mean amplitude of pulse-alone trials 
(Arbitrary units) 
188 (47.2) 196 (29.4) 230 (32.1) 207 (20.7) 0.39 2/61 .68 .01 
Mean percent prepulse inhibition 
(%PPI) 
61.2 (8.5) 41.3 (5.3) 32.1 (5.8) 41.3 (3.6) 3.82 2/61 .03 .11 
Percent early habituation of pulse-alone trials 
(between first and second block) 
40.6 (7.5) 26.4 (4.6) 15.9 (5.1) 24.9 (3.2) 3.67 2/61 .03 .11 
Percent total habituation of pulse-alone trials 
(between first and last block) 
59.0 (8.8) 38.6 (5.6) 33.8 (6.0) 40.4 (3.6) 2.82 2/61 .07 .09 
Habituation of pulse-alone trials across 6 blocks 
(linear gradient coefficient b) 
-28.0 (5.6) -12.6 (3.5) -18.7 (3.8) -17.7 (2.3) 2.86 2/61 .07 .09 
aANCOVA, means adjusted by covariates gender, age, smoking, and medication status. 
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